Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma.

GUIDELINE TITLE
Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma.

BIBLIOGRAPHIC SOURCE(S)
National Institute for Health and Clinical Excellence (NICE). Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma. London (UK): National Institute for Health and Clinical Excellence (NICE); 2009 Mar. 32 p. (Technology appraisal guidance; no. 169).

GUIDELINE STATUS
This is the current release of the guideline.

The guidance on this technology will be considered for review in February 2011.

abrir aquí para acceder al documento NGC AHRQ completo:
Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma.